Kyphoplasty Inpatient Billing Settlements: How Vendor Advice Reached Hospitals

Kyphoplasty inpatient billing settlements addressed allegations that hospitals charged Medicare for inpatient stays when patients could have received outpatient treatment. The procedure treated a spinal fracture. The alleged overbilling came from the decision to admit the patient. For someone who works in reimbursement, utilization review or device sales, the revealing part is where the case began: two former employees of the supplier, Kyphon, whose advice allegedly helped hospitals collect the higher payment.

Why Inpatient Status Changed the Kyphoplasty Bill

Kyphoplasty could bring a hospital more Medicare money when billed as inpatient care. The Justice Department’s account describes a minimally invasive procedure for certain spinal fractures, often caused by osteoporosis, that patients could safely and effectively receive as outpatients in many cases. It alleged that hospitals frequently chose inpatient billing to increase their Medicare payments.

The financial incentive sits between two hospital businesses. Medicare’s inpatient payment system generally pays a fixed amount for an admission, adjusted for the patient’s diagnosis group. Its outpatient system pays for the encounter. The classification puts the care into a different payment system before anyone argues about the price of the device. That is why hospital admission fraud can turn on the status decision itself.

The distinction matters to the people reviewing the chart. Whether the patient needed kyphoplasty and whether the patient needed an inpatient admission are separate questions. In these cases, the government’s allegation concerned the more expensive setting. The device seller’s reimbursement advice allegedly helped turn that choice into a repeatable hospital billing practice. The alleged sales pitch made the more expensive admission a selling point, with Medicare paying for it.

Medtronic Spine’s Settlement Came Before the Hospital Rounds

Medtronic Spine, Kyphon’s corporate successor, paid $75 million in May 2008 to resolve allegations about the supplier’s role. The government alleged that the company counseled hospitals to perform kyphoplasty as inpatient care, causing false claims to reach Medicare. That was the supplier’s payment, separate from the later hospital recoveries.

The two former Kyphon employees who brought the whistleblower case had worked as a reimbursement manager and a regional sales manager. Those jobs can reveal a connection between hospitals whose claims otherwise appear to come from separate institutions. A reimbursement manager may know the guidance customers received. A regional sales manager may know how that guidance traveled with the product. Here, the government alleged a connection between the seller’s advice and the hospitals’ inpatient claims. Someone outside a hospital could recognize a practice repeated inside several of them.

The Kyphoplasty Hospital Settlement Rounds

The 2013 and 2015 kyphoplasty hospital settlements extended a series of earlier hospital agreements. By February 2012, the government put the running total at more than forty hospitals and over $39 million.

The 2013 Kyphoplasty Hospital Settlements

The July 2, 2013 announcement covered 55 hospitals in twenty-one states, with settlements exceeding $34 million. By then, the hospital settlements covered more than 100 facilities. The whistleblowers’ announced share from this round was approximately $5.5 million.

Atrium Medical Center in Middletown, Ohio, agreed to pay about $4.2 million for one hospital, while twenty-three HCA hospitals agreed to pay about $7.1 million together. The alleged practice had reached individual hospitals and members of a large chain alike.

The 2015 Kyphoplasty Hospital Settlements

The December 18, 2015 round added 32 hospitals in fifteen states and more than $28 million. The government put the cumulative hospital settlements at approximately $105 million across more than 130 hospitals. The whistleblowers’ announced share from this round was approximately $4.75 million.

The round included the Cleveland Clinic and hospitals affiliated with Community Health Systems and Banner Health. Hospitals formerly owned by Health Management Associates also settled.

The manufacturer had already made its separate payment over the advice allegedly behind the claims. The government had pursued both ends of the same alleged billing practice.

The Same Admission Problem Beyond the Kyphoplasty Rounds

Dignity Health paid $37 million in a separate 2014 settlement covering allegations that thirteen hospitals overcharged Medicare and TRICARE for inpatient care. The Justice Department alleged that patients should have received less costly outpatient treatment. The allegations included inpatient billing for kyphoplasty and elective cardiovascular procedures.

That parallel matters to someone whose hospital sells a different procedure. The particular treatment can change while the payment incentive stays recognizable: an admission produces the higher bill. In kyphoplasty, the allegations also reached the vendor counseling the hospital about that choice.

What Vendor and Hospital Insiders Can Add

The people who understand a billing practice may work well upstream of the claim. The 2013 Asian Biomedicine review Hospital Manipulations in the DRG System grouped hospital payment manipulation into corporate, clinical and coding practices. Its point reaches beyond the coder’s desk:

That framework helps explain the kyphoplasty allegations. Reimbursement advice, the hospital’s admission practice and the claim submitted to Medicare occupy different parts of the business. An insider who understands the connection can explain how a commercial pitch reached a clinical decision and then a bill.

Claims data show another part of the picture. RAND’s 2024 report Methodologies to Measure Upcoding in Provider Settings found that most studies measured coding patterns across hospitals or geographic areas. For a healthcare insider, the useful addition is the explanation behind the pattern: what instruction circulated, how the admission decision followed it and what Medicare ultimately received.

The whistleblowers in these cases understood the supplier’s business from reimbursement and sales. Their roles are a concrete reason to look beyond the department that sent the claim. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know How the Advice Reached the Bill

If you know how a vendor’s reimbursement pitch became your hospital’s admission practice, speak with our whistleblower experts about that connection. We help you build your strongest whistleblower case around the people, decisions and claims you know, bring in whistleblower lawyers who understand device marketing and Medicare billing, and stay beside you through the case’s resolution.